newsfilter
← Latest News
Business Wire·

Ionis reports second quarter 2026 financial results and highlights progress on key programs

- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome